A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-14

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a first in human (FIH), open-label, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of B4T2-001 Autologous CAR T cells in subjects with advanced solid tumors including but not limited to advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, advanced pancreatic cancer, advanced non-small cell lung cancer (NSCLC), colorectal cancers (CRC) and metastatic breast cancer that tests positive for BT-001 target antigen according to Immunohistochemistry (IHC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors

NCT06072989

Advanced Solid Tumor

RECRUITING PHASE1

Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

NCT06238336

Hematological Malignancy

RECRUITING PHASE2/PHASE3

Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia

NCT04762485

T Lymphoblastic Leukemia/Lymphoma Mixed Phenotype Acute Leukemia Acute Myeloid Leukemia

UNKNOWN PHASE1/PHASE2

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

NCT03638206

B-cell Acute Lymphoblastic Leukemia Lymphoma Myeloid Leukemia +13 more

UNKNOWN PHASE1/PHASE2

CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors

NCT04691713

CAR Solid Tumor

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of B4T2-001 Autologous CAR T cells in subjects with BT-001 expressing advanced solid tumors. Patients who meet the eligibility criteria will receive B4T2-001 CAR T infusion after lymphodepletion. The lymphodepleting chemotherapy is administered on days -5, -4, and -3 before CAR T infusion using cyclophosphamide 300mg/m2 once daily and fludarabine 30mg/m2 once daily for 3 consecutive days. Doses may be adjusted for renal and/or hepatic insufficiency, or other comorbidities. The study is designed to include the following sequential steps: patient screening, pre-treatment, treatment and follow up for up to 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

B4T2-001 CAR T cells

Single Arm and Open Label study consisting of dose escalation study design followed by dose expansion phase at determined MTD. Treatment follows a lymphodepleting chemotherapy regimen

Group Type EXPERIMENTAL

B4T2-001 Autologous CAR T cells

Intervention Type BIOLOGICAL

Each subject will receive infusion with B4T2-001 autologous CAR T Cells

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

B4T2-001 Autologous CAR T cells

Each subject will receive infusion with B4T2-001 autologous CAR T Cells

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subjects have been fully informed of the possible risks and benefits of participating in this study and have voluntarily signed the informed consent form (ICF);
2. Age:18-70 years (including 18 and 70 years);
3. ECOG 0-1;
4. With an expected survival of more than 3 months;
5. Histologically or cytologically confirmed locally advanced or metastatic BT-001 positive malignant solid tumors (including but not limited to gastric or gastroesophageal junction adenocarcinoma, pancreatic cancer, non-small cell lung cancer and breast cancer), who have failed standard treatment, or for whom standard treatment is not available or applicable at this stage;
6. Having measurable or evaluable lesions according to RECIST 1.1 or the latest version;
7. Having sufficient bone marrow, liver and kidney functions (based on the normal value of the clinical trial site):

* Absolute neutrophil count (ANC) ≥ 1.5×109/L, platelets ≥ 75×109/L;
* Total serum bilirubin ≤ 1.5×upper limit of normal (ULN);
* Without liver metastases, alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) ≤ 2.5×ULN; with liver metastases, ALT, AST, or ALP ≤ 5×ULN;
* Serum creatinine (ScR) ≤ 1.5×ULN or creatinine clearance \> 50 mL/min (calculated according to Cockcroft Gault formula);
* International normalized ratio (INR) ≤ 1.5×ULN, APTT ≤ 1.5×ULN.
8. Adequate oxygen saturation (≥ 95%) can be maintained without oxygen inhalation;
9. Male or female patients of childbearing potential must agree to use effective methods of contraception (such as double-barrier contraceptive methods, condoms, oral or injectable contraceptives, and intrauterine devices) during the study period and within 1 year after infusion.

Exclusion Criteria

1. Patients who have received the following anti-tumor treatments prior to apheresis:

1. Cytotoxic therapy within 14 days;
2. Small molecule targeted therapy within 14 days or at least 5 half-lives, whichever is longer;
3. Therapy with monoclonal antibody within 21 days;
4. Immunomodulatory therapy within 7 days;
5. Radiotherapy within 14 days;
6. Traditional Chinese medicine with anti-tumor indications within 14 days;
7. Investigational agents or treatment within 28 days.
2. Previously treated with CAR-T/TCR-T cells therapy against any target or other cell therapies or therapeutic tumor vaccine;
3. Previously treated with any BT-001-targeted therapy;
4. Brain metastases with central nervous system symptoms;
5. Pregnant (positive pregnancy test prior to dosing) or breast-feeding women;
6. Allergic reaction to any drug and related excipients specified in protocol, e.g., lymphodepletion regimen (cyclophosphamide and fludarabine) and pre-infusion medication (acetaminophen and diphenhydramine), human serum albumin, tocilizumab, Erbitux/cetuximab, dimethyl sulfoxide (DMSO), and dextran 40;
7. Patients with active hepatitis B (hepatitis B surface antigen (HBsAg) is positive and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) \> 500IU/ml or lower limit of the research center \[Only when the detection limit of the research center is higher than 500IU/ml\]), or active hepatitis C (patients with positive HCV antibody but HCV-RNA \< lower limit of detection at the site are allowed), but patients receiving prophylactic antiviral therapy other than interferon are allowed;
8. Patients with a history of immunodeficiency, including those who are HIV-positive, or patients with other acquired or congenital immune deficiency, or a history of organ transplantation;
9. Patients with autoimmune diseases;
10. Patients with active infection requiring intravenous anti-infective therapy based on the investigator's judgment;
11. Patients who underwent major surgeries within 2 weeks prior to apheresis and not fully recovered;
12. The toxicity of previous anti-cancer therapy has not returned to less than or equal to Grade 1 as specified in CTCAE v5.0 or the latest version (except for hair loss, Grade 2 peripheral neuropathy, and stable hypothyroidism treated with hormone replacement therapy);
13. Patients with severe complications such as active gastrointestinal bleeding, intestinal obstruction, intestinal paralysis, interstitial pneumonia, pulmonary fibrosis, renal failure, and uncontrolled diabetes;
14. Patients with a history of acute myocardial infarction, unstable angina pectoris, stroke, or transient ischemic attack within 6 months prior to the enrollment, or with NYHA Class 2 or higher congestive heart failure;
15. Patients with chronic diseases requiring treatment with systemic corticosteroids or other immunosuppressants, received systemic corticosteroids (≥ 70 mg prednisone or equivalent dose of other corticosteroids) or other immunosuppressants within 7 days before apheresis, except for the following cases: local, ocular, intra-articular, intranasal, and inhaled glucocorticoid treatment; short term use of glucocorticoids for preventive treatment (such as prevention of contrast medium allergy);
16. Patients with the third space effusion that cannot be controlled clinically are not suitable for inclusion in the group according to the judgment of the investigator;
17. Patients with a history of uncontrollable mental illness;
18. Patients with gastric cancer have gastric perforation, pyloric obstruction, or complete biliary obstruction;
19. Patients with pancreatic cancer who have tumor causing biliary obstruction;
20. Any condition in which the investigator considers that the subject is not suitable to participate in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No